Mentioned as a negative comparison, cited as an example of a 'failed biotech story' similar to the speaker's thesis on ATYR.

Mentioned as a 'decent short' idea.

Mentioned as a past, highly successful short position for the speaker. It was his single biggest winner, contributing 43% to his portfolio's performance. The commentary is historical.

Mentioned as the speaker's biggest past profit, which came from a successful short position. No current forward-looking analysis was provided.

Mentioned as the speaker's biggest winning trade in the portfolio, up 44%, reflecting a past successful bullish call.

The speaker's biggest short position, calling it a 'piece of junk' with a price target of '$0.50 at some point' due to flawed clinical trial design.

The speaker holds a clear bearish position, explicitly stating, 'No, I'm still short INMB.'

Speaker is short the stock, believing it is 'basically worthless' and plans to cover the short position if the stock drops to $1.

The speaker is actively short and believes the stock has '75% downside' with a price target of $0.50, claiming the company has nothing of value in its pipeline and will waste its cash.

The analyst is extremely bearish, stating the Phase 2 trial for its drug Xpro failed. The company's positive spin on a subgroup is called 'a joke' and 'face-saving'. The plan to seek a partner is interpreted as a euphemism for 'giving up on the drug'.